August 11, 2026 05:19 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jharkhand student protest turns tense: Water cannons, lathicharge after Assembly march barricades breached | ‘Mother tongue is as pure as one's mother’: Vijay-led Tamil Nadu government makes Tamil Thaai Vazhthu mandatory in big language push | Indian envoy Kwatra cites US, UK laws to counter ‘myths’ around FCRA Bill | Jharkhand students march to assembly today: JPSC row escalates despite govt action | ‘A morning I will cherish’: Raghav Chadha meets PM Modi, shares photos from ‘enriching’ meeting | Delhi Mercedes crash kills 70-year-old woman: Cop’s son behind wheel, beer bottle found | Indian-origin woman accused of ‘visa fraud’ on X: US Attorney steps in with major clarification | US Senate passes Russia sanctions bill: India can face Trump’s 100% tariff threat | Expired meat, rotten vegetables found at Bengaluru's luxury hotels, legal action begins | 'I'm ready to be humiliated': Vijay, Udhayanidhi Stalin clash in Tamil Nadu Assembly over Cauvery dispute
Bharat Biotech-Covaxin
Image tweeted by @IndianEmbassyTR

Covaxin supplied to 18 states directly since May 1: Bharat Biotech

| @indiablooms | May 12, 2021, at 05:24 am

New Delhi/IBNS: Vaccine maker Bharat Biotech on Tuesday informed that it has directly supplied Covaxin to 18 states since May 1.

The pharmaceutical brand also urged people to get vaccinated assuring that it will continue a steady supply of vaccines to the states.

"COVAXIN® has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine. Get yourself and your loved ones vaccinated," the company said in a statement.

The company is supplying its vaccine directly to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu and Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh, and West Bengal.

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research (ICMR).

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

On April 29, Bharat Biotech reduced the price of Covaxin from Rs 600 per dose to Rs 400 for the state governments in view of the challenges faced by the already overstretched health system, the company had said.

The vaccination programme in India which started on Jan 16, was last month widely expanded to include citizens above 18 years of age as a part of the Centre's Liberalised Pricing & Accelerated National COVID-19 Vaccination strategy.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.